Soluble Mediator
AssigneeThe Walter and Eliza Hall Institute of Medical Research
InventorsEsther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.
Claims18
-47. (canceled)
A method of treating an inflammatory disorder in a mammalian subject, the method comprising:
- administering to the subject a composition comprising:
- a therapeutically effective amount of soluble mammalian CD52 glycoprotein;
- and
- a pharmaceutical acceptable carrier.
A method of treating an inflammatory disorder in a mammalian subject, the method comprising:
- administering to the subject a composition comprising:
- a therapeutically effective amount of a fusion protein comprising a first protein and a second protein, wherein the first protein is a soluble mammalian CD52 glycoprotein;
- and
- a pharmaceutical acceptable carrier.
A method of treating an autoimmune disorder in a mammalian subject, the method comprising:
- administering to the subject a composition comprising:
- a therapeutically effective amount of soluble mammalian CD52 glycoprotein, or a therapeutically effective amount of a fusion protein comprising a first protein and a second protein, wherein the first protein is a soluble mammalian CD52 glycoprotein;
- and
- a pharmaceutical acceptable carrier.
Dependencies are inferred from the claim text.